PL2638152T3 - Warianty rekombinowanych białek beta-glukocerebrozydaz ze zwiększoną stabilnością i zwiększoną zachowaną aktywnością katalityczną - Google Patents

Warianty rekombinowanych białek beta-glukocerebrozydaz ze zwiększoną stabilnością i zwiększoną zachowaną aktywnością katalityczną

Info

Publication number
PL2638152T3
PL2638152T3 PL11839428T PL11839428T PL2638152T3 PL 2638152 T3 PL2638152 T3 PL 2638152T3 PL 11839428 T PL11839428 T PL 11839428T PL 11839428 T PL11839428 T PL 11839428T PL 2638152 T3 PL2638152 T3 PL 2638152T3
Authority
PL
Poland
Prior art keywords
increased
variant
catalytic activity
recombinant beta
glucocerebrosidase proteins
Prior art date
Application number
PL11839428T
Other languages
English (en)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL2638152T3 publication Critical patent/PL2638152T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11839428T 2010-11-08 2011-11-08 Warianty rekombinowanych białek beta-glukocerebrozydaz ze zwiększoną stabilnością i zwiększoną zachowaną aktywnością katalityczną PL2638152T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US41218010P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
PL2638152T3 true PL2638152T3 (pl) 2017-02-28

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11839428T PL2638152T3 (pl) 2010-11-08 2011-11-08 Warianty rekombinowanych białek beta-glukocerebrozydaz ze zwiększoną stabilnością i zwiększoną zachowaną aktywnością katalityczną

Country Status (19)

Country Link
US (4) US8962564B2 (pl)
EP (2) EP3144386B1 (pl)
JP (2) JP6073796B2 (pl)
KR (1) KR101901467B1 (pl)
CN (2) CN105296447A (pl)
BR (1) BR112013011152A2 (pl)
CA (1) CA2817011C (pl)
CY (1) CY1118843T1 (pl)
DK (1) DK2638152T3 (pl)
ES (2) ES2604490T3 (pl)
HR (1) HRP20161560T1 (pl)
HU (1) HUE030932T2 (pl)
LT (1) LT2638152T (pl)
PL (1) PL2638152T3 (pl)
PT (1) PT2638152T (pl)
RS (1) RS55405B1 (pl)
SI (1) SI2638152T1 (pl)
SM (1) SMT201600431B (pl)
WO (1) WO2012064709A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157248A1 (en) * 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
JP7600124B2 (ja) 2019-02-04 2024-12-16 フリーライン セラピューティクス リミテッド ポリヌクレオチド
US20220325265A1 (en) 2019-09-09 2022-10-13 Hoffmann-La Roche Inc. Glucocerebrosidase mutants
JP7830343B2 (ja) * 2020-03-29 2026-03-16 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド ゴーシェ病の処置において使用するためのベータ－グルコセレブロシダーゼのバリアント
EP4643868A2 (en) * 2020-07-29 2025-11-05 Spur Therapeutics Limited Mutated beta-glucocerebrosidase with improved stability
US20250145979A1 (en) * 2022-01-31 2025-05-08 Nippon Shokubai Co., Ltd. Protein having glucocerebrosidase activity and method for producing same
JPWO2023145812A1 (pl) * 2022-01-31 2023-08-03
US20250129351A1 (en) * 2022-01-31 2025-04-24 Nippon Shokubai Co., Ltd. Recombinant glucocerebrosidase protein having improved enzyme activity or improved stability
JP2025514645A (ja) 2022-04-12 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー 中枢神経系に対して標的化された融合タンパク質
EP4599052A4 (en) * 2022-10-08 2026-03-04 Lingyi Biotech Co Ltd POLYNUCLEOTIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH GCASE DEFICIENCY
TW202532096A (zh) * 2023-12-08 2025-08-16 美商戴納立製藥公司 經修飾之葡萄糖腦苷脂酶多肽及其使用方法
WO2026006173A1 (en) * 2024-06-24 2026-01-02 Denali Therapeutics Inc. Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム　コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
ATE138686T1 (de) 1988-12-23 1996-06-15 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
JP2002511851A (ja) * 1997-04-30 2002-04-16 リージェンツ オブ ジ ユニバーシティー オブ ミネソタ 肝細胞の遺伝的病変を修正するためのリコンビナジェニックオリゴヌクレオ塩基のｉｎ ｖｉｖｏでの使用
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
JP2002522509A (ja) * 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US6328958B1 (en) 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
AU2352201A (en) * 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
EP1272620A2 (en) 2000-04-06 2003-01-08 Cytoclonal Pharmaceutics, Inc. Expression system for efficiently producing clinically effective glucocerebrosidase
JP2004504016A (ja) * 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
EP1613264A4 (en) 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
JP2010525084A (ja) * 2007-04-26 2010-07-22 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画
CN104530068B (zh) * 2007-05-22 2017-05-03 阿米库斯治疗学公司 用于制备异法戈明的化合物
US20090148887A1 (en) 2007-11-02 2009-06-11 The Scripps Research Institute Genetically encoded boronate amino acid
MX2010004807A (es) 2007-11-02 2010-08-02 Scripss Res Inst Evolucion dirigida utilizando proteinas que comprenden aminoacidos no naturales.

Also Published As

Publication number Publication date
RS55405B1 (sr) 2017-04-28
CN105296447A (zh) 2016-02-03
US20150216950A1 (en) 2015-08-06
SI2638152T1 (sl) 2016-12-30
SMT201600431B (it) 2017-01-10
BR112013011152A2 (pt) 2016-11-29
WO2012064709A2 (en) 2012-05-18
LT2638152T (lt) 2016-12-12
CA2817011A1 (en) 2012-05-18
JP2017099390A (ja) 2017-06-08
JP2014500722A (ja) 2014-01-16
KR101901467B1 (ko) 2018-11-02
US20160184408A1 (en) 2016-06-30
EP2638152B1 (en) 2016-08-31
EP2638152A4 (en) 2014-04-09
US20170157220A1 (en) 2017-06-08
JP6457559B2 (ja) 2019-01-23
CN103314105B (zh) 2015-11-25
KR20140009238A (ko) 2014-01-22
US20130344054A1 (en) 2013-12-26
US9821038B2 (en) 2017-11-21
EP2638152A2 (en) 2013-09-18
US9254313B2 (en) 2016-02-09
PT2638152T (pt) 2016-10-25
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
US9566316B2 (en) 2017-02-14
HRP20161560T1 (hr) 2016-12-30
ES2743825T3 (es) 2020-02-20
CA2817011C (en) 2019-04-02
CY1118843T1 (el) 2018-01-10
EP3144386A1 (en) 2017-03-22
ES2604490T3 (es) 2017-03-07
DK2638152T3 (en) 2016-12-12
CN103314105A (zh) 2013-09-18
HUE030932T2 (en) 2017-06-28
JP6073796B2 (ja) 2017-02-01
EP3144386B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
SI2638152T1 (sl) Variantni in rekombinantni proteini beta-glukocerebrozidaze s povišano stabilnostjo in povišano ohranjeno katalitično aktivnostjo
IL280949B (en) Ph20 polypeptide variants, formulations and uses thereof
HUE037256T2 (hu) Béta-glükozidáz aktivitású polipeptid alkalmazása
PL2588492T3 (pl) Polipeptyd mający aktywność beta-glukozydazy i jego zastosowania
ZA201207969B (en) Vanadia-based denox catalysts and catalyst supports
ZA201501541B (en) Supported catalyst and active form thereof, and preparation method and use thereof
PT3434775T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
SG2014011894A (en) Catalyst support and catalysts prepared therefrom
PH12013501775A1 (en) Polymeric acid catalysts and uses thereof
SG11201500345WA (en) Catalytic reduction of nox with high activity catalysts
GB2478638B (en) Exhaust system comprising nox storage catalyst and csf
SI2938352T1 (sl) Ciklični kationski peptidi z antimikrobno aktivnostjo
ZA201504075B (en) Core-shell particles with catalytic activity
ZA201108577B (en) Cellulase variants with improved expression, activity and/or stability, and use thereof
EP2523689A4 (en) IL-22-FC WITH HEPCIDINE EFFECT
SG10201507873YA (en) Catalyst supports, catalysts and their manufacture and use
PL2407147T3 (pl) Kompozycja o działaniu bioregeneracyjnym, wzmacniającym i eutrofizującym
EP2580231A4 (en) PEPTIDES, CONSTRUCTIONS AND USES THEREOF
DK3392268T3 (da) Polypeptider med transgalactosylerende aktivitet
EP2830638A4 (en) DIASPIRIN-NETWORKED PEGYLATED HEMOGLOBIN
GB2492266B (en) Horseshoe with splaying feature and flexibility
IL226108A0 (en) Highly efficient catalysts, their preparation and use
ZA201209441B (en) Aspergillus aculeatus derived polypeptides having c4-dicarboxylic acid transporter activity and polynucleotides encoding same
GB2503802B (en) Caspofungin analog, and Preparation Method and Uses thereof
EP2417151B8 (fr) Peptides cycliques à activité antiparasitaire